載入中
NASDAQHealthcareMedical - Instruments & Supplies
最新資料
US$26.91
−US$0.07 · -0.26%
Kestra Medical Technologies, Ltd. operates at the intersection of wearable medical technology and digital healthcare. Its core mission is to revolutionize patient outcomes in cardiovascular disease through intelligent, intuitive, and connected monitoring and therapeutic intervention solutions. The company's flagship offering is the Cardiac Recovery System (CRS) platform, which it develops and commercializes. This unified solution seamlessly integrates cardiac monitoring, therapeutic treatment, digital health capabilities, and patient support services. A central component of the CRS is the ASSURE WCD, a wearable cardioverter defibrillator specifically engineered to protect individuals at elevated risk of sudden cardiac arrest (SCA). Beyond its hardware, the CRS platform also encompasses a suite of integrated digital solutions and services. These are designed to foster enhanced engagement and oversight between patients and healthcare providers, ultimately striving for improved patient well-being. Founded in 2014, the company is headquartered in Kirkland, Washington.
收盤時
US$26.91
−US$0.07 · -0.26%
盤後
US$26.91
US$0.00 · 0.00%
10月12日 下午4:39 ET
盤中時間採用ET。市場資料可能有所延遲。
Kestra Medical Technologies, Ltd. operates at the intersection of wearable medical technology and digital healthcare. Its core mission is to revolutionize patient outcomes in cardiovascular disease through intelligent, intuitive, and connected monitoring and therapeutic intervention solutions. The company's flagship offering is the Cardiac Recovery System (CRS) platform, which it develops and commercializes. This unified solution seamlessly integrates cardiac monitoring, therapeutic treatment, digital health capabilities, and patient support services. A central component of the CRS is the ASSURE WCD, a wearable cardioverter defibrillator specifically engineered to protect individuals at elevated risk of sudden cardiac arrest (SCA). Beyond its hardware, the CRS platform also encompasses a suite of integrated digital solutions and services. These are designed to foster enhanced engagement and oversight between patients and healthcare providers, ultimately striving for improved patient well-being. Founded in 2014, the company is headquartered in Kirkland, Washington.
日內區間
目前US$26.91
52週區間
目前US$26.91
盤中時間採用ET。市場資料可能有所延遲。
Kestra Medical Technologies, Ltd. operates at the intersection of wearable medical technology and digital healthcare. Its core mission is to revolutionize patient outcomes in cardiovascular disease through intelligent, intuitive, and connected monitoring and therapeutic intervention solutions. The company's flagship offering is the Cardiac Recovery System (CRS) platform, which it develops and commercializes. This unified solution seamlessly integrates cardiac monitoring, therapeutic treatment, digital health capabilities, and patient support services. A central component of the CRS is the ASSURE WCD, a wearable cardioverter defibrillator specifically engineered to protect individuals at elevated risk of sudden cardiac arrest (SCA). Beyond its hardware, the CRS platform also encompasses a suite of integrated digital solutions and services. These are designed to foster enhanced engagement and oversight between patients and healthcare providers, ultimately striving for improved patient well-being. Founded in 2014, the company is headquartered in Kirkland, Washington.
日內區間
目前US$26.91
52週區間
目前US$26.91
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2026會計年度 | 2025會計年度 | 2024會計年度 | 2023會計年度 |
|---|---|---|---|---|
| 營收 | 9512.7萬 USD | 5981.5萬 USD | 2781.4萬 USD | 763萬 USD |
| 銷貨成本 | 4626.3萬 USD | 3560.5萬 USD | 2745.2萬 USD | 1828.1萬 USD |
| 毛利 | 4886.4萬 USD | 2421萬 USD | 36.2萬 USD | −1065.1萬 USD |
| 研究與開發 | 1948.3萬 USD | 1565.2萬 USD | 1549萬 USD | 1575.6萬 USD |
| 銷售、一般及管理費用 | 1.64億 USD | 1.15億 USD | 6993.5萬 USD | 5401.4萬 USD |
| 營業費用 | 1.84億 USD | 1.31億 USD | 8542.5萬 USD | 6977萬 USD |
| 利息收入 | 835.1萬 USD | 319.9萬 USD | — | — |
| 利息支出 | 754.7萬 USD | 773.4萬 USD | 623萬 USD | 562.9萬 USD |
| 折舊和攤銷 | 870.9萬 USD | 796.8萬 USD | 1156萬 USD | 485.5萬 USD |
| 營業利益 | −1.35億 USD | −1.06億 USD | −8506.3萬 USD | −8042.1萬 USD |
| 淨利 | −1.32億 USD | −1.14億 USD | −9412萬 USD | −8423.8萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$30.67
上漲空間 13.97%評級樣本有限，僅4項
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI2387.51萬0.00%2.3兆 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM1895.34萬0.02%787.4億 USD0.19%US$277.9-0.37%
iShares Russell 2000 Growth ETFIWO659.98萬0.05%139.17億 USD0.24%US$353.71-0.86%
First Trust Small Cap Growth AlphaDEX FundFYC652.54萬0.48%13.49億 USD0.70%US$114.85-0.44%
Vanguard Extended Market ETFVXF580.92萬0.01%954億 USD0.05%US$233.52-0.63%
Schwab U.S. Small-Cap ETFSCHA473.26萬0.02%218.24億 USD0.03%US$32.66-0.40%
iShares U.S. Medical Devices ETFIHI438.36萬0.12%35.74億 USD0.37%US$52.79+2.03%
Vanguard Russell 2000 ETFVTWO396.62萬0.02%180億 USD0.06%US$112.27-0.35%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMiShares Russell 2000 Growth ETFIWOFirst Trust Small Cap Growth AlphaDEX FundFYCVanguard Extended Market ETFVXFSchwab U.S. Small-Cap ETFSCHAiShares U.S. Medical Devices ETFIHIVanguard Russell 2000 ETFVTWOAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
